Explore the words cloud of the NO-ESKAPE project. It provides you a very rough idea of what is the project "NO-ESKAPE" about.
The following table provides information about the project.
Coordinator |
UNIVERSITEIT UTRECHT
Organization address contact info |
Coordinator Country | Netherlands [NL] |
Project website | http://martinlab.nl |
Total cost | 2˙000˙000 € |
EC max contribution | 2˙000˙000 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2016-COG |
Funding Scheme | ERC-COG |
Starting year | 2017 |
Duration (year-month-day) | from 2017-06-01 to 2022-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITEIT UTRECHT | NL (UTRECHT) | coordinator | 2˙000˙000.00 |
Antibiotic resistance poses an alarming threat to global health. Most worrisome are the so-called “ESKAPE” pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumanii, P. aeruginosa, and Enterobacter species), a collection of organisms capable of escaping the effects of almost all conventional antibiotics. Key to combating drug-resistant bacteria is the identification of new antibacterial targets and the ability to exploit these targets with novel and unconventional antibiotics.
The microbial world produces a wealth of antibacterial compounds that, while not suitable for therapeutic use, operate by diverse and unique modes of action. This proposal describes innovative approaches aimed at the discovery and development of such compounds as leads towards novel antibiotics with entirely new modes of action. Using a multidisciplinary approach, firmly grounded in synthetic organic chemistry, I will prepare and validate new antibiotics that target the ESKAPE pathogens by exploiting mechanisms critical to their survival and/or resistance.
To tackle the Gram-positive ESKAPE pathogens a number of new approaches to interfering with bacterial cell wall biosynthesis will be examined. Specifically, novel (semi)synthetic compounds capable of binding to and sequestering various bacterial cell wall precursors will be prepared and their antibiotic activity assessed. To address the Gram-negative ESKAPE pathogens, inhibitors of the metallo-beta-lactamase enzymes responsible for much of their antibiotic resistance will be pursued. These inhibitors will be achieved via a combination of rational design strategies and innovative natural product screening approaches.
The 21st century threat of a post-antibiotic era makes clear the need for innovation in antibacterial drug discovery. The strategies outlined in this proposal address this threat head-on with the aim of delivering valuable lead compounds in pursuit of novel antibiotics.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Kamaleddin H. M. E. Tehrani, Nathaniel I. Martin β-lactam/β-lactamase inhibitor combinations: an update published pages: 1439-1456, ISSN: 2040-2503, DOI: 10.1039/c8md00342d |
MedChemComm 9/9 | 2019-12-16 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-ESKAPE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NO-ESKAPE" are provided by the European Opendata Portal: CORDIS opendata.
Just because we can, should we? An anthropological perspective on the initiation of technology dependence to sustain a child’s life
Read MoreA need for speed: mechanisms to coordinate protein synthesis and folding in metazoans
Read MoreUnderstanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell
Read More